Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Chemotherapy (DEVEC) in Elderly Non-fit Aggressive B-Cell Lymphoma
NCT03161054Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2017
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prednisone, vinorelbine, etoposide and cyclophosphamide in aggressive B-cell lymphoma, sponsored by Fondazione Italiana Linfomi. Primary endpoints: Complete Remission Rate at 30 months and Incidence of adverse events at 30 months. Started Sep 2017; status: completed.
02
Drugs
prednisonevinorelbineetoposidecyclophosphamide
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT03161054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161054.